Solentim sets new standards in productivity with the launch of ICON™ and STUDIUS™; accelerating assurance rich workflows in the development of new biologics

Bournemouth, UK, 25th January 2021 / Sciad Newswire / Solentim, the trusted global leader in cell therapy workflows enabling the creation, isolation and characterization of high value cells, is delighted to launch two new solutions to enhance the development of therapeutic antibodies. ICON™ is a benchtop system for the rapid stratification of high productivity clones and STUDIUS™ is a proprietary software platform that delivers unparalleled data on each cell’s journey through cell line development.

The all-in-one ICON system assesses specific productivity using rapid on-board assays for the three critical quality attributes of titer, cell number and cell viability. Using plate-based imaging for static plate cell counting and cell suspension automated cell counting with viability for fed-batch, ICON generates normalized cell productivity data. This information enables cell line development scientists to separate the promising clones from the rest, saving resources and accelerating workflows.

STUDIUS is Solentim’s bespoke data management solution for cell line development. The over-arching platform is designed for Solentim’s instruments to provide control, management and reporting in the pursuit of lead candidates. STUDIUS delivers an unparalleled perspective on the journey of each individual cell, from seeding to selection, and intelligently manages verified information from multiple sources to enable scientists to select high value cells. Importantly, STUDIUS protects data, providing data auditing and integrity with a suite of tools applicable for laboratories working under 21 CFR Part 11 compliance. Using the novel HISTORYTREE™ visualization, STUDIUS maps each cell’s journey, presenting all the necessary cell data for regulatory approval in one report.

Dr Mark Truesdale, CEO, Solentim, said: “Our cell line development ecosystem of instruments – Cell Metric^®, VIPS™ and now ICON – provides the optimal workflow solution for seeding, growing and selecting the highest value cells with quality evidence of assurance of clonality. Our protected ecosystem ensures data integrity, and our data-driven reporting prepares you for regulatory approval from day one.”

To find out how ICON and STUDIUS can take your cell line development workflow to the next level, or to arrange a product demo, please contact us.

ENDS

For further information, contact:

Corporate Contacts:
Solentim Ltd
Duncan Borthwick, Global Marketing Manager
T: +44 (0)1202 798510          
E: duncan.borthwick@solentim.com

PR Contact:
Sciad Communications Ltd
Emma Pickup/Richard Anderson
T: +44 (0)20 3405 7892
E: solentim@sciad.com

Notes to Editors

About Solentim
Solentim is the trusted global leader in cell therapy workflows enabling the creation, isolation and characterization of high value cells. In the pursuit of new biological medicines, our data rich portfolio of industry accepted technologies drives accelerated development of Master Cell Banks. For our customers, which include most of the world’s leading pharmaceutical and biotherapeutics companies, we are the partner of choice for facilitating the highest level of assurance in cell line development for therapeutic protein and viral vector production.

Our portfolio of proven and innovative instruments (including VIPS™, Cell Metric^®, Cell Metric^® CLD and ICON™) are designed for single cell cloning and assurance of monoclonality. Combined with enabling reagents (including InstiGRO™ and Leap-In Transposase^®) from our partners, and our unparalleled domain expertise, we transform the speed and efficiency of clonally-derived Master Cell Bank development. Our customers trust in our technology to ensure they are confidently prepared for regulatory review.